Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Predica Diagnostics B.V., Nijmegen, The Netherlands.
J Neurooncol. 2022 Sep;159(3):647-655. doi: 10.1007/s11060-022-04106-4. Epub 2022 Aug 17.
Cancers of an unknown primary site (CUPs) have a dismal prognosis, and the situation is even worse for CUPs patients with brain metastases (BM-CUPs). This study aims to give better insight into the occurrence and survival of BM-CUPs patients.
Cases were selected from the Netherlands Cancer Registry (1,430 BM-CUPs/17,140 CUPs). Baseline characteristics between CUPs patients with and without BM were tested using chi-square tests and Mann-Whitney U tests. Patients' overall survival (OS) times were estimated by the Kaplan-Meier method and prognostic factors on OS was assessed using Cox proportional hazards regression analyses.
The proportion of BM-CUPs patients among CUPs increased from 8% in 2009-2010 to 10% in 2017-2018 (p < 0.001). Most patients presented with multiple brain lesions (53%). Survival of BM-CUPs improved over time: one-year OS increased from 10% for patients diagnosed in 2009-2010 to 17% (2017- 2018) (p < 0.01), and median survival times increased from 1.8 months to 2.2 months. Independent predictors of poor survival were multiple (HR 1.25; p < 0.01) or unknown (HR 1.48; p < 0.01) locations of BM, unknown/poorly/undifferentiated carcinoma histology (HR 1.53; p < 0.01), or clinical symptoms of BM (HR 1.74; p < 0.01), accompanying liver metastasis (HR 1.43; p < 0.01) and more than one metastatic site outside the brain compared to none (HR 1.52; p < 0.01).
The incidence of patients with BM-CUPs is steadily increasing over time and overall prognosis remains dismal. Our results, however, show distinct patient subgroups that exhibit comparatively better outcomes, and more predictors may likely still be identified.
不明原发灶癌(CUP)患者预后较差,而合并脑转移(BM-CUPs)的患者情况更糟。本研究旨在深入了解 BM-CUPs 患者的发病和生存情况。
从荷兰癌症登记处(1430 例 BM-CUPs/17140 例 CUPs)中选择病例。使用卡方检验和曼-惠特尼 U 检验比较 CUPs 患者有无 BM 的基线特征。采用 Kaplan-Meier 法估计患者的总生存(OS)时间,采用 Cox 比例风险回归分析评估 OS 的预后因素。
CUPs 患者中 BM-CUPs 患者的比例从 2009-2010 年的 8%增加到 2017-2018 年的 10%(p<0.001)。大多数患者表现为多发脑转移灶(53%)。BM-CUPs 的生存状况随时间改善:2009-2010 年诊断的患者一年 OS 率从 10%增加到 17%(2017-2018 年)(p<0.01),中位生存时间从 1.8 个月增加到 2.2 个月。预后不良的独立预测因素包括多发(HR 1.25;p<0.01)或未知(HR 1.48;p<0.01)的 BM 位置、未知/差/未分化的癌组织学(HR 1.53;p<0.01)或 BM 的临床症状(HR 1.74;p<0.01)、肝转移(HR 1.43;p<0.01)以及与无脑外多发转移灶相比的单个转移灶(HR 1.52;p<0.01)。
随着时间的推移,BM-CUPs 患者的发病率稳步上升,整体预后仍然较差。然而,我们的研究结果显示出明显的患者亚组,其预后相对较好,可能还有更多的预测因素有待发现。